PMID- 34048997
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1879-1379 (Electronic)
IS  - 0022-3956 (Linking)
VI  - 139
DP  - 2021 Jul
TI  - Registered clinical studies investigating psychedelic drugs for psychiatric 
      disorders.
PG  - 71-81
LID - S0022-3956(21)00288-0 [pii]
LID - 10.1016/j.jpsychires.2021.05.019 [doi]
AB  - Psychedelics are a hallucinogenic class of psychoactive drugs with the primary 
      effect of activating non-ordinary states of consciousness. Due to the positive 
      preliminary findings of these drugs in the treatment of psychiatric disorders, 
      the number of registered clinical studies has risen significantly. In this paper, 
      clinical studies registered on clinicaltrials.gov that evaluate the treatment of 
      any psychiatric disorder with psychedelics (excluding ketamine) are summarized 
      and analyzed. 70 registered studies were identified from a clinicaltrials.gov 
      search on December 3, 2020. The majority of studies aim to investigate 
      methylenedioxymethamphetamine (MDMA) (45.7%) and psilocybin (41.4%). Studies 
      evaluating ayahuasca, lysergic acid diethylamide (LSD), ibogaine hydrochloride, 
      salvia divinorum, 5-MeO-DMT and DMT fumarate were less common at 1.4%, 4.2%, 
      2.8%, 1.4%, 1.4% and 1.4% of total registered studies, respectively. Most of the 
      studies on MDMA, psilocybin, ayahuasca and salvia divinorum investigated their 
      therapeutic effect on post-traumatic stress disorder (PTSD) and major depressive 
      disorder (MDD). LSD was investigated for MDD, anxiety, and severe somatic 
      disorders and ibogaine hydrochloride was investigated for substance and alcohol 
      use disorders. 5-MeO-DMT and DMT fumarate were both investigated for MDD. Only 
      21/70 registered studies had published results with the majority not yet 
      completed. In view of the large number of ongoing studies investigating 
      psychedelics, it is imperative that these studies are considered by researchers 
      and stakeholders in deciding the most relevant research priorities for future 
      proposed studies.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Siegel, Ashley N
AU  - Siegel AN
AD  - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, 
      Canada.
FAU - Meshkat, Shakila
AU  - Meshkat S
AD  - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, 
      Canada.
FAU - Benitah, Katie
AU  - Benitah K
AD  - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, 
      Canada.
FAU - Lipsitz, Orly
AU  - Lipsitz O
AD  - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, 
      Canada.
FAU - Gill, Hartej
AU  - Gill H
AD  - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, 
      Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
FAU - Lui, Leanna M W
AU  - Lui LMW
AD  - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, 
      Canada.
FAU - Teopiz, Kayla M
AU  - Teopiz KM
AD  - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, 
      Canada.
FAU - McIntyre, Roger S
AU  - McIntyre RS
AD  - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, 
      Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; 
      Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, 
      Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
FAU - Rosenblat, Joshua D
AU  - Rosenblat JD
AD  - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, 
      Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 
      Electronic address: joshua.rosenblat@uhn.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210518
PL  - England
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
RN  - 0 (Hallucinogens)
RN  - 0 (Pharmaceutical Preparations)
RN  - 2RV7212BP0 (Psilocybin)
SB  - IM
MH  - *Alcoholism
MH  - *Depressive Disorder, Major/drug therapy
MH  - *Hallucinogens/therapeutic use
MH  - Humans
MH  - *Pharmaceutical Preparations
MH  - Psilocybin
OTO - NOTNLM
OT  - Ayahuasca
OT  - DMT
OT  - Depression
OT  - Ibogaine
OT  - LSD
OT  - MDMA
OT  - Post-traumatic stress disorder
OT  - Psilocybin
OT  - Psychedelics
OT  - Psychiatric disorders
EDAT- 2021/05/29 06:00
MHDA- 2021/07/06 06:00
CRDT- 2021/05/28 20:16
PHST- 2020/12/24 00:00 [received]
PHST- 2021/04/22 00:00 [revised]
PHST- 2021/05/01 00:00 [accepted]
PHST- 2021/05/29 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2021/05/28 20:16 [entrez]
AID - S0022-3956(21)00288-0 [pii]
AID - 10.1016/j.jpsychires.2021.05.019 [doi]
PST - ppublish
SO  - J Psychiatr Res. 2021 Jul;139:71-81. doi: 10.1016/j.jpsychires.2021.05.019. Epub 
      2021 May 18.